Results 71 to 80 of about 8,230 (206)
Reviews in Medical Virology, Volume 35, Issue 6, November 2025.ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency, characterised by impaired antibody production, immune dysregulation, and a broad spectrum of clinical manifestations. Gastrointestinal involvement is frequent, affecting up to 20% of patients and significantly contributing to morbidity and ...
Györgyi Műzes, Ferenc Sipos
wiley +1 more source
Biotechnology Journal, Volume 20, Issue 10, October 2025.Graphical Abstract and Lay Summary Transposase‐mediated integration provides a robust alternative for generating stable lentiviral vector producer cell lines. While yielding slightly lower maximum titers than concatemeric‐array methods, it requires less DNA, accelerates recovery, and delivers more consistent performance, supporting scalable LVV ...
Jona Röscheise +7 more
wiley +1 more source
Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]
, 2015 OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye +6 more
core +1 more source
Health Science Reports, Volume 8, Issue 10, October 2025.ABSTRACT Background and Aims Hemophilia A and B are two of the most common bleeding disorders. Genetic risk factors are associated with the development of autoantibodies released in hemophilia patients against alternative factors and are the most important problems associated with the care of these patients. Objective In this study, we reviewed genetic
Fatemeh Zeylabi +2 more
wiley +1 more source
X-Linked Agammaglobulinemia Presenting with Secondary Hemophagocytic Syndrome: A Case Report
Case Reports in Medicine, 2013 Introduction. Coincidence of X-linked agammaglobulinemia (XLA) and secondary hemophagocytic syndrome (sHS) is atypical. Both diseases are rare and pathogenesis of the latter one is not clearly known. Case Presentation. A 5-year-old boy was diagnosed both
Can Ozturk +3 more
doaj +1 more source
Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age. [PDF]
, 2015 BACKGROUND:Hizentra® (IGSC 20%) is a 20% liquid IgG product approved for subcutaneous administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD). There is limited information about the use of IGSC 20 %
Atkinson, Thomas Prescott +10 more
core +2 more sources
CRISPR/Cas9‐edited tumor‐associated immune cells in cancer immunotherapy
VIEW, Volume 6, Issue 5, October 2025.The recent advancements in the application of CRISPR/Cas9‐edited tumor‐associated immune cells in cancer therapy are summarized, including T lymphoid cells, natural killer cells, macrophages, and B lymphoid cells et al., exhibiting a potential impact on the pathological status of cancer. This review also addresses the current challenges associated with
Yuhui Ma +6 more
wiley +1 more source
Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
The Turkish Journal of Pediatrics, 2019 The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as ...
Şükrü Çekiç +4 more
doaj +1 more source
Chronic Enteroviral Meningoencephalitis in a Boy with X-Linked Agammaglobulinemia [PDF]
, 2000 Os autores apresentam um caso clínico de encefalite crónica a enterovírus num rapaz de 9 anos com agamaglobulinémia congénita ligada ao cromossoma X (doença de Bruton). Apesar da terapêutica intraventricular com doses elevadas de gamaglobulina, registou-
Alves, A +4 more
core
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]
, 2014 Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M +6 more
core +2 more sources